LEUKEMIA, MYELOID, ACUTE

This Phase 3 trial tests whether adding ivosidenib (a targeted pill) to standard azacitidine helps adults with a specific IDH1-mutated acute myeloid leukemia (AML) who cannot have intensive chemotherapy. About 146 participants receive either the combo or a placebo plus azacitidin…

This phase 3 trial compares a two-drug combination (pevonedistat plus azacitidine) against azacitidine alone in 302 older or unfit adults newly diagnosed with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The main goal is to see if the combination …

This early-stage trial tests a new drug called JNJ-89853413 in 64 people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, with a second part looking a…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This early-stage study tests a new drug called bleximenib combined with other leukemia treatments for people with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A or NPM1). The main goals are to find the best dose and check for side effects. About 196 partici…

This phase 2 trial tests whether adding an experimental antibody called cusatuzumab to the standard drugs venetoclax and azacitidine helps people with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 140 adults who cannot have intensive chemotherapy. P…

This early-phase study tests a new drug called cusatuzumab alongside usual treatments for adults with acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The main goal is to check the safety and side effects of the combination. About 61 participants will receive …

This phase 2 trial is testing whether an oral chemotherapy drug called azacitidine (CC-486) can help prevent acute myeloid leukemia from coming back in Chinese patients who are already in complete remission after initial treatment. About 34 participants will receive either the dr…

This study tests two experimental drugs (AG-120 and AG-221) that target specific genetic mutations (IDH1 or IDH2) found in some acute myeloid leukemia (AML) patients. Each drug is combined with a standard chemotherapy (azacitidine) and compared to azacitidine alone. The trial enr…

This study tests an electronic program that combines mindfulness and music therapy for people undergoing stem cell transplants for blood cancers. The goal is to see if it improves quality of life and reduces symptoms like pain. About 60 adults will participate, and the program in…